May 15 |
TAK
|
Takeda dengue vaccine gets WHO clearance |
May 14 |
TAK
|
Update: Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute |
May 14 |
TAK
|
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute |
May 14 |
TAK
|
Scilex wins court approval for Takeda settlement |
May 14 |
TAK
|
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting |
May 13 |
TAK
|
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday? |
May 13 |
TAK
|
Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy |
May 13 |
TAK
|
AC Immune rockets 47% on Alzheimer's therapy deal with Takeda |
May 13 |
TAK
|
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune |
May 13 |
TAK
|
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate |
May 13 |
TAK
|
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease |
May 10 |
TAK
|
Catalyst's New CEO Has Big Ideas For The Small Biotech |
May 10 |
TAK
|
Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript |
May 9 |
TAK
|
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50% |
May 9 |
TAK
|
Takeda tackles $900m restructuring plan after generics hurt annual profits |
May 9 |
TAK
|
Takeda Pharmaceutical Company Limited 2023 Q4 - Results - Earnings Call Presentation |
May 9 |
TAK
|
Takeda seeks efficiency as operating profit slumps |
May 9 |
TAK
|
Takeda targets ‘efficiency’ in restructuring, pipeline cuts |
May 9 |
SHYF
|
Shyft Group (NASDAQ:SHYF) Has Affirmed Its Dividend Of $0.05 |
May 9 |
TAK
|
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss |